Metabolic Disorders/ Diabetes

Displaying 1 - 7 of 7


LUMASIL: A Low-Level Light Therapy Device for Treating Diabetic Foot Ulcers

LumaSiL is a low-level light therapy (LLLT) producing device which aims to accelerate wound healing and reduce the incidence of infection in diabetic foot ulcers (DFUs). There is no treatment option using this technology that actively encourages diabetic foot ulcer healing, complements current procedures, and maintains patient compliance. Complications like infection often require the need for surgical intervention such as lower-extremity amputation. Previous studies have shown that exposing wounds to dose-specific levels of light can reduce wound size and promote healing. Incorporated into a standard of care, the total-contact cast, this device transfers LED light from a power source to the wound site in order to introduce an active healing component for diabetic foot ulcers.


Licensing Contact

Masood Machingal

615.343.3548

Targeting microRNAs as a Treatment for Vascular Disease

Vanderbilt researchers have identified a highly expressed microRNA crucial in angiotensin induced hypertension; and developed a therapeutic strategy that focuses on local or systemic administration of antisense microRNA to inhibit microRNA expression as treatment for vascular diseases. Promising data in animal models reveals that the inhibition of such microRNA not only prevents fibrosis but also reverses previously established aortic stiffening.


Licensing Contact

Jody Hankins

615.322.5907

Anti-Insulin Transgenic Mice for the Study of B cells in Type I Diabetes

Two mouse models produce anti-insulin antibodies with enhanced insulin binding capacity, and hence model accelerated TID disease progression. A third mouse model features altered VDJ sequence in the immunoglobulin heavy chain (VH281 Tg line) which produces the non-insulin binding  mutant version of the anti-insulin antibody mAB 125, which models reduced disease progression and severity. Hence these mice can be very useful tools in investigating TID disease mechanism as well as potential therapeutics.


Licensing Contact

Jody Hankins

615.322.5907

Inventors

James Thomas
Research Tools
Animal Model

Rabbit-Anti-mouse Pancreatic and Duodenal Homebox Gene-1 Antibody

This research targets Pdx-1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Christopher Wright

Pancreas Specific Trangenic Mice Overexpressing Either Transmembrane Heparin-binding EGF-like Growth Factor or Secreted HB-EGF

This research targets HB-EGF.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Anna Means
Research Tools
Animal Model

Insulin 2-Akita Heterozygous Mice (DBA/2J strain)

This research targets Ins2 .


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Animal Model

Insulin Promoter Driven Insulin-Luciferase Transgenic Mouse (CD-1 Background)

This research targets INS1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Alvin Powers
Research Tools
Animal Model